**TO THE EDITOR:** According to the 2008 World Health Organization (WHO) guidelines, eosinophilia is associated with hematologic diseases such as chronic eosinophilic leukemia-not otherwise specified (CEL-NOS); idiopathic hypereosinophilic syndrome (HES) or idiopathic hypereosinophilia; and myeloid and lymphoid neoplasms with eosinophilia, and abnormalities of *PDGFRA*, *PDGFRB* or *FGFR1* \[[@B1]\]. CEL is diagnosed in cases with increased blasts or cytogenetic/clonal abnormalities. We report 2 cases of myeloid and lymphoid neoplasms (CEL) with the *FIP1L1-PDGFRA* rearrangement.

CASES
=====

The first case, 27-year-old man was referred to our hospital for a dyspnea workup. The echocardiogram revealed severe tricuspid valve regurgitation and moderate mitral valve regurgitation. A valvuloplasty was performed and dizziness developed after the surgery. Brain magnetic resonance imaging revealed microbleeding in the right temporo-occipital lobe. He was referred to the hemato-oncology department for evaluation of eosinophilia. The laboratory findings were as follows: WBC count, 21.1×10^9^/L (eosinophil count, 13.0×10^9^/L); Hb, 9.1 g/dL; and platelet count, 99.0×10^9^/L. In addition, parasite antibodies for *Clonorchis sinensis*, *Paragonimus westermani*, *Cysticercus cellulosae*, and *Sparganosis* were negative. The number of eosinophils in the peripheral blood smear was increased ([Fig. 1A](#F1){ref-type="fig"}). Analysis of the bone marrow aspirate showed that 1.95% of all nucleated cells were blasts and eosinophils were increased ([Fig. 1B](#F1){ref-type="fig"}). Conventional cytogenetic analysis revealed a normal karyotype (46,XY). Fluorescence in situ hybridization (FISH) for *FIP1L1-PDGFRA* using the Vysis 4q12 Tri-Color probe (Abbott, Des Plaines, USA) was positive ([Fig. 2A, B](#F2){ref-type="fig"}). We confirmed the *FIP1L1-PDGFRA* rearrangement by reverse transcription-polymerase chain reaction (RT-PCR) and sequencing analysis ([Fig. 2D, E](#F2){ref-type="fig"}). The primers for RT-PCR and sequencing analysis were as follows: forward, 5\'-TCAGACAAGTACTGCCTCCAGA-3\' and reverse, 5\'-AG GCTCCCAGCAAGTTTACA-3\'. According to the 2008 WHO guidelines, a diagnosis of myeloid and lymphoid neoplasm (CEL) associated with *FIP1L1-PDGFRA* was established. Tyrosine kinase inhibitor treatment with imatinib mesylate was initiated and the eosinophil counts decreased.

The second case, 23-year-old man was referred to our hospital for a workup as eosinophilia had been detected in a routine health checkup. The laboratory findings were as follows: WBC count, 70.0×10^9^/µL (eosinophil count, 55.3×10^9^/L); Hb, 10.1 g/dL; and platelet count, 131.0×10^9^/L. The number of eosinophils in the peripheral blood smear was increased ([Fig. 1C](#F1){ref-type="fig"}). In the bone marrow aspirate, 90% of all nucleated cells were eosinophils. Infiltration by eosinophils was observed in the bone marrow section ([Fig. 1D](#F1){ref-type="fig"}). Conventional cytogenetic analysis revealed a normal karyotype (46,XY) and FISH for *FIP1L1-PDGFRA* was positive ([Fig. 2C](#F2){ref-type="fig"}). Tyrosine kinase inhibitor treatment with imatinib mesylate was initiated and the eosinophil counts decreased.

DISCUSSION
==========

The *FIP1L1-PDGFRA* rearrangement caused by a cryptic deletion of 800-kb on chromosome 4q12, which contains the *CHIC2* gene \[[@B2]\], cannot be detected in conventional chromosomal studies; FISH or RT-PCR must be used. The prevalence of *PDGFRA*, *PDGFRB* or *FGFR1* rearrangements is generally low. The *FIP1L1-PDGFRA* rearrangement is the most commonly found with an incidence of approximately 23%, but this varies (range, 3-56%) depending on the HES patient population \[[@B3]\], and is predominantly found in males. In a Korean study \[[@B4]\], only 1 case with a *PDGFRA* rearrangement was detected among 34 hypereosinophilia patients who were suspected of having clonal eosinophilia. Until now, few cases of *PDGFRA*, *PDGFRB*, or *FGFR1* rearrangements have been reported in Korea \[[@B4], [@B5], [@B6], [@B7], [@B8], [@B9]\], and these are summarized in [Table 1](#T1){ref-type="table"}.

The initial clinical manifestation of HES involves dermatologic, pulmonary, and gastrointestinal symptoms \[[@B10]\]. However, the presence of neurologic or cardiac signs and symptoms increases with disease progression or delayed diagnosis \[[@B10]\]. Severe cardiac complications include endomyocardial fibrosis, valve scarring, and embolism. Our patients also showed dyspnea, cardiac signs (valve regurgitation), and renal involvement (Case 1). Therefore, clinicians need to be alert for the presence *PDGFRA*, *PDGFRB*, or *FGFR1* rearrangements in eosinophilia patients with systemic symptoms, especially those associated with the cardiopulmonary or renal systems.

In conclusion, we report 2 cases of CEL with the *FIP1L1-PDGFRA* rearrangement. Eosinophilia with *PDGFRA*, *PDGFRB*, or *FGFR1* rearrangements is rare in the general population. However, its prevalence is high in HES patients (range, 3-56%) \[[@B3]\], and FISH or RT-PCR must be used for its detection. Unusual cardiopulmonary or gastrointestinal symptoms with severe complications may be observed initially. Therefore, clinicians must consider *PDGFRA*, *PDGFRB* or *FGFR1* rearrangements in patients with eosinophilia presenting with these symptoms and perform FISH or RT-PCR.
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![Peripheral blood (PB) smear and bone marrow (BM) aspirate findings of first case **(A, B)** and second case **(C, D)**. **(A)** Eosinophilia (13.0×10^9^/L) was observed in the PB (Wright-Giemsa, ×1,000). **(B)** Dysplastic eosinophils (sparse and mixed granules) were increased in the BM aspirate (Wright-Giemsa, ×1,000). **(C)** Eosinophilia (55.316×10^9^/L) was observed in the PB (Wright-Giemsa, ×1,000). **(D)** The BM section was packed with eosinophils (hematoxylin-eosin, ×400).](br-50-58-g001){#F1}

![Fluorescence in situ hybridization (FISH) for the FIP1L1-PDGFRA rearrangement, and reverse transcription - polymerase chain reaction (RT-PCR) and sequencing analysis. **(A)** Schematic representation of the 4q12 region and FISH probe. **(B)** Loss of the orange signal indicates deletion of the 4q12 region (white arrow) in first case. **(C)** FISH results for second case. **(D)** RT-PCR was performed using RNA extracted from the patient\'s (first case) white blood cells (lane 1). EOL-1 cells were used as a positive control (lane 2). Size marker (M). **(E)** Sequencing analysis of the RT-PCR products revealed the fusion of *FIP1L1*, exon 12 and truncated *PDGFRA*, exon 12 (breakpoint is between the 84^th^ and 85^th^ nucleotides of exon 12). *FIP1L1*, Ensemble Gene ID ENSG00000145216; PDGFRA, Ensemble Gene ID, ENSG00000134853.](br-50-58-g002){#F2}

###### Summary of Korean cases with PDGFRA/PDGRB or FGFR1 abnormalities.
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Abbreviations: AMML, acute myelomonocytic leukemia; CEL, chronic eosinophilic leukemia; CMML, chronic myelomonocytic leukemia; MD, minimal differentiation; MM, multiple myeloma; NA, not available.
